Aldurazyme (Recombinant Human Alpha-L-Iduronidase)

BIOLOGICAL3 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Hurler SyndromeHurler's SyndromeHurler-Scheie SyndromeMucopolysaccharidosis IScheie Syndrome

Phase 2

A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

CompletedNCT00146757

Genzyme, a Sanofi CompanyHurler-Scheie Syndrome, Hurler Syndrome, Mucopolysaccharidosis I +1

Start: 2002-10-31End: 2005-05-31Updated: 2015-04-03

Phase 3

Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I) Disease

CompletedNCT00258011

Genzyme, a Sanofi CompanyHurler-Scheie Syndrome, Hurler Syndrome, Mucopolysaccharidosis I +1

Start: 2005-12-31End: 2006-10-31Updated: 2014-03-07

Phase 4

A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease

CompletedNCT00144781

Genzyme, a Sanofi CompanyHurler-Scheie Syndrome, Hurler's Syndrome, Mucopolysaccharidosis I +1

Start: 2004-12-31End: 2006-01-31Updated: 2015-04-03